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Summary A high incidence of bladder cancer has been documented in an area of chronic arsenic (As) exposure. This study investigates the
characteristics of As-associated (n = 49) and other (n = 64) bladder cancers. A higher histological grading was observed for the As-exposed
tumours (P = 0.04), but no other difference in pathobiological features or prognosis was found between the two groups.
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Arsenic (As) is widely distributed in the environment, and human
exposure can be through environmental, agricultural and occupa-
tional routes. The commonest route of exposure is through inges-
tion of water containing inorganic As. In an endemic area of
chronic arsenicism from drinking high-As artesian well water in
south-western Taiwan, residents have been suffering from the
so-called blackfoot disease (BFD), a peripheral vascular disease
(Tseng, 1968). Significantly high incidence and mortality rates of
transitional cell carcinoma of the urinary bladder, up to 30 times
greater than those in other regions, have been reported from the
BFD-endemic area (Su et al, 1985; Chen et al, 1990; Chiang et al,
1993). Odds ratios as high as 3.6 have been established in multi-
plicative analyses for long-term users of deep wells in the area
relative to the general population, and dose-response relationships
between arsenic concentrations in the well water and the occur-
rence ofbladder cancer have been demonstrated (Chen et al, 1986,
1990, 1992; Chiou et al, 1995).
A preliminary study reported unusualp53 mutational patterns in
bladder tumours (n = 13) from the endemic area (Shibata et al,
1994), and there is a general concern that the As-associated
bladder cancer might have distinct clinicopathological features.
The present study was therefore performed in an attempt to
address the above question.
MATERIALS AND METHODS
Patient population and definition of arsenic exposure
A total of 113 patients with bladder cancer were collected from the
National Cheng Kung University Hospital, which is close to the
BFD-endemic area in Taiwan. The history of As exposure was
established by interviewing the patients or their families about the
wells they had drunk from during their daily lives (Tseng, 1968).
Those who claimed to have consumed for more than 10 years
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deep-well water in the township where As levels in the well water
exceed 0.05 mg 1-' were designated as As exposed (Smith et al,
1992). Those who had resided in these townships for 50 years or
longer were also included in this category, irrespective of their
water-drinking history. The remaining patients were considered as
unexposed to As.
Clinicopathological characteristics
The tumours were graded by the WHO classification (1973) and
staged according to the recommendation of the American Joint
Committee on Cancer (1983) with a survey of all the clinical
details. Clinical follow-up ranged from 12 months to 64 months
(median, 30 months).
Immunohistochemical investigation
Monoclonal anti-c-erbB-2 antibody (Triton Diagnostics, Alameda,
CA, USA) was used to examine the expression ofgene products as
previously described (Lee et al, 1994). Those exhibiting membra-
nous reactions in part ofa tumour were classified as '+', and those
with diffuse immunostaining ofall tumour cells as '++'.
Statistics
The relationship between As exposure and the characteristics of
bladder cancer was analysed by chi-square tests. Student's t-test
was used to compare the differences between age at diagnosis and
tumour size in the two exposure groups. The Kaplan-Meier
method and log-rank test were used to compare the survival time
and the risk of recurrence. The Cox proportional hazards regres-
sion model was used to identify the independent prognostic factors
for recurrence or patient survival. Only those variables with a
P-value < 0.05 were considered significant.
RESULTS
A history of As-exposure was identified in 49 (43.4%) out of 113
patients (Table 1). Patients in the As-exposed group had a signifi-
cantly higher histological grading (P = 0.04) than those in the non-
As-exposed group; however, no apparent correlation was observed
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Table 1 Association between the history of arsenic exposure and
characteristics of bladder cancer
Parameters As (n = 49) Non-As (n = 64) P-value
Age 66.3 1.3 62.6 ± 1.7 0.10
Sex 0.14
Male 27 44
Female 22 20
Size (cm) 2.8 ± 0.3 2.1 ± 0.2 0.08
Shape 0.19
Papillary 30 46
Nodular 16 14
Multiplicity 0.86
Single 23 29
Multiple 23 31
Grade 0.04a
1 6 11
2 20 36
3 21 13
Stage 0.26
Ta 15 27
T1-T3 27 29
N+,M+ 5 3
ap< 0.05.
Table 2 Prognostic significance of biologic indicators and c-erbB-2
overexpression in bladder cancer
Parameters Recurrence Death
Total
Grade 0.72 0.76
Stage 0.30 0.003a
Multiplicity 0.54 0.08
As exposure 0.63 0.52
c-erbB-2 0.41 0.96
As exposure
Grade 0.36 0.32
Stage 0.38 0.01b
Multiplicity 0.29 0.37
c-erbB-2 0.84 0.54
Non-As exposure
Grade 0.93 0.96
Stage 0.59 0.10
Multiplicity 0.23 0.15
c-erbB-2 0.33 0.53
ap< 0.005; bp< 0.05.
with tumour size, staging, gross configuration, multiplicity, patient
gender or age at diagnosis.
Among the 99 patients studied immunohistochemically (data
not shown), 54 (54.5%) had c-erbB-2 overexpression (61.4% and
49.1% positive in the As-exposed and non-As-exposed groups
respectively) (P = 0.23). Overall, there was a positive relationship
between c-erbB-2 expression and histological grade (P < 0.05);
but it did not have an apparent association with the remaining
biological indicators.
Multivariate analysis (Table 2) revealed that tumour stage was
the only significant factor in predicting patient survival among all
patients (P = 0.003) and in the As-exposed group (P = 0.01), but
that this was not true for non-As tumours (P = 0.10). No one para-
meter was satisfactory in predicting the risk ofrecurrence, although
again stage had the lowest value among the four variables.
DISCUSSION
The association of As exposure with a high incidence or mortality
ofbladder cancer has been consistently demonstrated in a number
of epidemiological studies, principally from Taiwan (Chen et al,
1986; Cuzick et al, 1992; Chiang et al, 1993; Chiou et al, 1995;
Tsuda et al, 1995). The lifetime risk of developing bladder cancer
in BFD-endemic areas from daily As intake of 10,g kg-' is
1.2 x 10-2 and 1.7 x 10-2 for men and women, respectively (Chen
et al, 1992). In this study, we attempted to investigate the patho-
biological features ofbladder cancer associated with As exposure.
Patients with exposure history were found to have a higher histo-
logical grade of bladder cancer than those without exposure.
However, there was no significant correlation between As expo-
sure and tumour stage, the most important prognostic factor for
bladder cancer. As exposure also did not apparently alter the
expression ofc-erbB-2 in tumour cells. Furthermore, the exposure
history had no prognostic significance. Altogether, As-associated
bladder cancer showed no remarkable pathobiological differences
in comparison with non-exposed tumours.
Currently, the mechanism by which inorganic As induces
bladder cancer remains unclear. Although the p53 mutation has
been found in some As-associated bladder cancer, As fails to
produce gene mutations at specific genetic loci in vitro (Rossman
et al, 1980). Repeated injections of As and its compounds cannot
definitely induce tumours in animal experiments (Chiang et al,
1993). However, As could enhance the effects of other chemical
carcinogens (Lee et al, 1986). Its major methylated metabolite,
dimethylarsinic acid, appears to act as a promoter of carcino-
genesis (Dong and Luo, 1993). Therefore, arsenic may be a
co-factor in the neoplastic transformation.
Apart from bladder cancer, BFD patients also had a signifi-
cantly higherrisk ofdeveloping cancers ofthe skin, lung, liver and
kidney after adjustment for age, sex and cigarette smoking (Chen
et al, 1986, 1990, 1992; Chiou et al, 1995). It has been suggested
that systemic deposits of the methylated metabolites of arsenic in
the relevant tissues are of local aetiological importance also for
these malignancies (Chiou et al, 1995). Whatever the actions of
methylated As metabolites may be, our data, using bladder cancer
as a prototype, suggest that As-associated cancer does not show
any obvious pathobiological difference when compared with non-
exposure cancer. This observation, however, needs to be verified
using a larger series ofpatients in the future.
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